Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.

Pereira MA, Warner BM, Knobloch TJ, Weghorst CM, Lubet RA, Steele VE, Casto BC.

Int J Cancer. 2012 Sep 15;131(6):1277-86. doi: 10.1002/ijc.27395. Epub 2012 Jan 31.

2.
3.
4.

Chemoprevention: mouse colon and lung tumor bioassay and modulation of DNA methylation as a biomarker.

Pereira MA, Tao LH, Wang W, Gunning WT, Lubet R.

Exp Lung Res. 2005 Mar;31(2):145-63.

PMID:
15824018
5.

Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice.

Gunning WT, Kramer PM, Lubet RA, Steele VE, Pereira MA.

Exp Lung Res. 2000 Dec;26(8):757-72.

PMID:
11195469
6.

Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice.

Huang EH, Johnson LA, Eaton K, Hynes MJ, Carpentino JE, Higgins PD.

Dig Dis Sci. 2010 Nov;55(11):3086-94. doi: 10.1007/s10620-010-1157-x. Epub 2010 Feb 26.

PMID:
20186482
7.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.

Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ.

PLoS One. 2013 Oct 10;8(10):e76340. doi: 10.1371/journal.pone.0076340. eCollection 2013.

8.

Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.

Suh N, Reddy BS, DeCastro A, Paul S, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Janakiram NB, Steele V, Rao CV.

Cancer Prev Res (Phila). 2011 Nov;4(11):1895-902. doi: 10.1158/1940-6207.CAPR-11-0222. Epub 2011 Jul 15.

9.

Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin.

Lu G, Xiao H, You H, Lin Y, Jin H, Snagaski B, Yang CS.

Clin Cancer Res. 2008 Aug 1;14(15):4981-8. doi: 10.1158/1078-0432.CCR-07-1860.

10.

Prevention of mouse lung tumors by targretin.

Pereira MA, Kramer PM, Nines R, Liu Y, Alyaqoub FS, Gunning WT, Steele VE, Lubet RA.

Int J Cancer. 2006 May 1;118(9):2359-62.

11.

Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.

Kuo WY, Wu CY, Hwu L, Lee JS, Tsai CH, Lin KP, Wang HE, Chou TY, Tsai CM, Gelovani J, Liu RS.

Oncotarget. 2015 Apr 20;6(11):8663-75.

12.

The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.

Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT.

Carcinogenesis. 2013 Jan;34(1):199-210. doi: 10.1093/carcin/bgs319. Epub 2012 Oct 6.

13.

Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.

Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV.

Cancer Res. 2006 Jul 15;66(14):7370-7.

14.

Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice.

Gunning WT, Kramer PM, Steele VE, Pereira MA.

Cancer Res. 2002 Aug 1;62(15):4199-201.

15.

Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.

Chien CW, Yao JH, Chang SY, Lee PC, Lee TC.

Toxicol Appl Pharmacol. 2011 Nov 15;257(1):59-66. doi: 10.1016/j.taap.2011.08.018. Epub 2011 Aug 25.

PMID:
21889949
16.

Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.

Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS, Conney AH.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5480-7.

17.

Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.

Siddiquey MN, Nakagawa H, Iwata S, Kanazawa T, Suzuki M, Imadome K, Fujiwara S, Goshima F, Murata T, Kimura H.

Cancer Sci. 2014 Jun;105(6):713-22. doi: 10.1111/cas.12418. Epub 2014 May 13.

18.

Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ.

Mol Cancer Ther. 2009 Jul;8(7):1799-807. doi: 10.1158/1535-7163.MCT-09-0055. Epub 2009 Jul 7.

19.

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.

Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr, Zimmer SG, Modesitt SC.

Gynecol Oncol. 2007 Mar;104(3):596-601. Epub 2006 Oct 16.

PMID:
17049973
20.

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.

Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Donà G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2995-3000. Epub 2002 Feb 26.

Supplemental Content

Support Center